MRI with gadofosveset: A potential marker for permeability in myocardial infarction

Abstract

Background and aimsAcute ischemia is associated with myocardial endothelial damage and microvessel formation, resulting in leakage of plasma albumin into the myocardial extravascular space. In this study, we tested whether an albumin-binding intravascular contrast agent (gadofosveset) allows for improved quantification of myocardial permeability compared to the conventional extracellular contrast agent Gd-DTPA using late gadolinium enhancement (LGE) and T1 mapping in vivo.MethodsMI was induced in C57BL/6 mice (n = 6) and cardiac magnetic resonance imaging (CMR) was performed at 3, 10 and 21 days post-MI using Gd-DTPA and 24 h later using gadofosveset. Functional, LGE and T1 mapping protocols were performed 45 min post-injection of the contrast agent.ResultsLGE images showed that both contrast agents provided similar measurements of infarct area at all time points following MI. Importantly, the myocardial R1 measurements after administration of gadofosveset were higher in the acute phase-day 3 (R1 [s−1] = 6.29 ± 0.29) compared to the maturation phase-days 10 and 21 (R1 [s−1] = 4.76 ± 0.30 and 4.48 ± 0.14), suggesting that the uptake of this agent could be used to stage myocardial remodeling. No differences in myocardial R1 were observed after administration of Gd-DTPA at different time points post-MI (R1 [s−1] = 3d: 3.77 ± 0.37; 10d: 2.74 ± 0.06; 21d: 3.35 ± 0.26). The MRI results were validated by ex vivo histology that showed albumin leakage in the myocardium in the acute phase and microvessel formation at later stages.ConclusionsWe demonstrate the merits of an albumin-binding contrast agent for monitoring changes in myocardial permeability between acute ischemia and chronic post-MI myocardial remodeling.

Prelamin A mediates myocardial inflammation in dilated and HIV-associated cardiomyopathies

“…For detection of myocardial scarring by T1 mapping (52), anesthetized mice were subject to MRI before and 25 minutes after i.p. administration of 0.75 mmol/kg of gadofosveset trisodium (Ablavar, Lantheus Medical Imaging), a gadolinium-based contrast agent.…”

Emerging methods for the characterization of ischemic heart disease: ultrafast Doppler angiography, micro-CT, photon-counting CT, novel MRI and PET techniques, and artificial intelligence

“…Notably, only 18 Fgalacto-RGD has been described in patients with myocardial infarction [49]. Recently, Lavin et al [51] developed a new gadolinium-based albumin-binding contrast agent, gadofosveset, and demonstrated the feasibility of imaging vascular permeability in a murine model of myocardial infarction.…”

Assessment of Albumin ECM Accumulation and Inflammation as Novel In Vivo Diagnostic Targets for Multi-Target MR Imaging

“…Iron oxide particles are used to detect intraplaque macrophage accumulation based on shortening T2/T2* relaxation times. T2*-weighted MR images show a significant signal loss in the vessel wall [26]. Ferumoxytol (Feraheme ® , AMAG-Pharmaceuticals, Waltham, MA, USA) is used as an off-label MRI contrast agent.…”